Registry-listed formulations

This catalogue entry has no confirmed scientific concept.

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

0 source entries across 0 studies. This list may not include all unresolved or historical entries.

    Success Metrics

    Completion Rate
    0%(0/2)
    Active Trials
    0(0%)
    Terminated
    2(100%)

    Phase Distribution

    Phase 3
    2
    100%

    Phase Distribution

    0

    Early Stage

    0

    Mid Stage

    2

    Late Stage

    Phase Distribution2 total trials
    Phase 3Large-scale testing
    2(100.0%)

    Highest Phase Reached

    Phase 3

    Trial Status & Enrollment

    Completion Rate

    0.0%

    0 of 2 finished

    Non-Completion Rate

    100.0%

    2 ended early

    Currently Active

    0

    trials recruiting

    Total Trials

    2

    all time

    Status Distribution
    Terminated(2)

    Detailed Status

    Terminated2

    Development Timeline

    Analytics

    Development Status

    Total Trials
    2
    Active
    0
    Success Rate
    0.0%
    Most Advanced
    Phase 3

    Trials by Phase

    Phase 32 (100.0%)

    Trials by Status

    terminated2100%

    Recent Activity

    0 active trials
    Showing 2 of 2
    terminatedphase_3

    Study to Assess the Efficacy and Safety of LX201 for Prevention of Corneal Allograft Rejection Episodes and Graft Failure in Subjects at Increased Immunological Risk

    NCT00447187
    terminatedphase_3

    Study to Assess LX201 for Prevention of Corneal Allograft Rejection or Graft Failure in Subjects Who Have Experienced One or More Rejection Episodes Following Penetrating Keratoplasty

    NCT00447642

    Clinical Trials (2)

    Showing 2 of 2 trials
    NCT00447187Phase 3

    Study to Assess the Efficacy and Safety of LX201 for Prevention of Corneal Allograft Rejection Episodes and Graft Failure in Subjects at Increased Immunological Risk

    Terminated
    NCT00447642Phase 3

    Study to Assess LX201 for Prevention of Corneal Allograft Rejection or Graft Failure in Subjects Who Have Experienced One or More Rejection Episodes Following Penetrating Keratoplasty

    Terminated

    All 2 trials loaded

    Drug Details

    Intervention Type
    Drug
    Total Trials
    2